Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)

Hanusch Claus; Schneeweiss Andreas; Loibl Sibylle; Untch Michael; Paepke Stefan; Kuemmel Sherko; Jackisch Christian; Huober Jens; Hilfrich Joern; Gerber Bernd; Eidtmann Holger; Denkert Carsten; Costa Serban; Blohmer Jens Uwe; Engels Knut; Burchardi Nicole; von Minckwitz Gunter

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)

【24h】

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)

机译：AFatinib和Trastuzumab双重阻断作为NEo辅助治疗接受紫杉烷-蒽环类药物化疗（DAGNE）的局部晚期或可手术乳腺癌患者（GBG-70）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Dual anti-HER2 blockade with trastuzumab/pertuzumab or trastuzumab/lapatinib in combination with anthracycline/taxane-based chemotherapy can reach pathologic complete response (pCR) rates of up to 60% in HER2-positive breast cancer. The DAFNE (Dual blockade with AFatinib and trastuzumab as NEoadjuvant treatment) phase II study (NCT015591477) investigated a dual blockade with the irreversible pan-HER inhibitor afatinib and trastuzumab in this setting.

机译：目的：曲妥珠单抗/培妥珠单抗或曲妥珠单抗/拉帕替尼双重抗HER2阻断剂与蒽环类/紫杉烷类化学疗法联合使用可在HER2阳性乳腺癌中达到高达60％的病理完全缓解率。 DAFNE（使用AFatinib和曲妥珠单抗作为新的辅助治疗双重阻断）II期研究（NCT015591477）研究了在这种情况下使用不可逆的pan-HER抑制剂afatinib和曲妥珠单抗的双重阻断。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2015年第13期|共8页
作者
Hanusch Claus; Schneeweiss Andreas; Loibl Sibylle; Untch Michael; Paepke Stefan; Kuemmel Sherko; Jackisch Christian; Huober Jens; Hilfrich Joern; Gerber Bernd; Eidtmann Holger; Denkert Carsten; Costa Serban; Blohmer Jens Uwe; Engels Knut; Burchardi Nicole; von Minckwitz Gunter;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70) (vol 21, pg 2924, 2015) [J] . Hanusch C., Schneeweiss A., Loibl S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第17期

机译：与AFATINIB和TRASTUZIMAB的双封闭式作为Neoadjuvant治疗，用于接受含有含有化疗-DAFNE（GBG-70）的含少炸蛋白 - 蒽环蛋白（GBG-70）的紫罗兰甘油（GBG-70）（第21卷，PG 2924,2015）
2. A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer [J] . Rimawi Mothaffar F., Aleixo Sabina B., Alarcon Rozas Ashley, Clinical breast cancer . 2015,第2期

机译：阿法替尼对曲妥珠单抗对拉帕替尼对局部晚期HER2阳性乳腺癌患者的新辅助，随机，开放标签II期试验
3. Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable, locally advanced, or inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：II期，开放标签，随机化，生物标志物研究免疫介导的免疫介导的术治疗，局部晚期或炎症HER2阳性乳腺癌患者患者。 immunher试验代表Gruppo oncologico Italiano di Ricerca Clinica（Goirc）
4. Characterizing tumor changes during neoadjuvant treatment of locally advanced breast cancer patients (LABC) using dynamicenhanced magnetic resonance imaging (DE-MRI) [C] . Oana I. Craciunescu, Ellen L. Jones, Kimberly L. Blackwell, Society of Photo-Optical Instrumentation Engineers (SPIE);SPIE Proceedings . 2005

机译：使用动态增强磁共振成像（DE-MRI）表征局部晚期乳腺癌患者（LABC）新辅助治疗期间的肿瘤变化
5. Intenzivnej?e neoadjuvantno zdravljenje lokalno napredovalnega raka danke =Intensified neoadjuvant treatment of locally advanced rectal cancer [D] . Golo, Danijela. 2018

机译：强烈的Neoadjuvant治疗局部晚期癌症射线=加强Neoadjuvant治疗局部晚期直肠癌
6. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer [O] . Takahiro Kogawa, Tamer M. Fouad, Diane D. Liu, 2016

机译：高的HER2 / Centromeric探针对17号染色体荧光原位杂交比率预测接受曲妥珠单抗新辅助治疗的HER2过表达局部晚期乳腺癌的患者的病理完全缓解和生存结果
7. Correction: Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) [O] . 2016

机译：校正：用AFATINIB和TRASTUZUMAB的双封闭式作为Neoadjuvant治疗，用于接受含有化疗-DAFNE的含紫罗兰甘油蛋白（GBG-70）

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)

摘要

著录项

相似文献

相关主题

期刊订阅